2021: Aduhelm’s Contested Approval

On This Day in Health: June 7, 2021

On June 7, 2021, the U.S. Food and Drug Administration granted accelerated approval to Aduhelm, the Alzheimer's drug aducanumab developed by Biogen with Eisai. The federal decision authorized a treatment aimed at amyloid plaques in the brain, rather than only the symptoms of dementia. Biogen, based in Cambridge, Massachusetts, presented the approval as a major milestone after years without a new Alzheimer's medicine. Yet the authorization carried a crucial qualification. It relied on a biological change considered reasonably likely to predict benefit, while requiring another clinical trial to establish whether patients actually gained the expected benefit in memory, thinking or daily function.

Alzheimer's disease progressively damages brain cells and the connections between them. Amyloid deposits are one of its characteristic abnormalities, and researchers had spent years testing whether removing them could alter the illness. Aducanumab is a monoclonal antibody designed to bind aggregated forms of amyloid beta and help reduce plaque. The underlying scientific question extended beyond whether a scan could show less amyloid. Patients and families needed to know whether treatment could meaningfully slow the difficulties that shape daily life. Those are related questions, but they require different evidence. The distinction became central to understanding both the promise of Aduhelm and the controversy surrounding the FDA's decision.

Two large late-stage studies had produced inconsistent clinical results, complicating interpretation of the treatment's effectiveness. The FDA nevertheless concluded that the reduction in amyloid plaque supported the accelerated pathway. This route permits earlier access for serious illnesses on the basis of an appropriate surrogate endpoint, with an obligation to verify clinical benefit afterward. Approval did not establish that Aduhelm cured Alzheimer's or restored lost abilities. Treatment also involved repeated intravenous infusions and safety concerns, including imaging abnormalities associated with swelling or small areas of bleeding in the brain. Evaluating a new medicine therefore required considering its evidence, monitoring demands and risks together, rather than treating regulatory authorization as a complete answer to every clinical question.

Later events underscore how provisional the June milestone remained. On January 31, 2024, Biogen announced that it would discontinue Aduhelm's development and commercialization and terminate the ENVISION confirmatory study. The company described the move as a resource-prioritization decision, not one driven by new safety or efficacy concerns. That later announcement should be distinguished from what the FDA had decided in 2021. The approval's lasting importance lies partly in the debate it sharpened over evidence standards, surrogate measures and access to treatments for devastating disease. Aduhelm made the gap between changing a disease marker and demonstrating a patient benefit unusually visible, leaving an important case study in how medical hope, scientific uncertainty and regulatory responsibility meet.